Following recent meetings with the FDA and European Medicines Agency (EMA), Mereo Biopharma is designing a Phase III study of alvelestat to treat alpha-1-antitrypsin deficiency-associated lung disease.
Unlearn.AI, which has built a machine learning platform that creates “digital twin” profiles of patients in clinical trials, has raised $15 million to expand partnerships and accelerate regulatory approval.
The new financing will help the Boston-based biotech accelerate the development of its siRNA-based therapies for immuno-dermatology indications.
Med Ad News sat down with Anthony Hemsey of Heal Studios to talk about how his media company, recently launched with his cousin and Head of Production Lauren Veteri, seeks use documentary-style storytelling to build awareness around disease states through the eyes of patients, healthcare professionals, and innovators in the lifescience arena.
Rapport Therapeutics, a clinical-stage biotech aiming to develop precision medicines for neurological disorders, launched Tuesday with $100 million in Series A financing.
Consolidation is driven by larger pharma companies snapping up smaller players to access new therapies recently approved by the FDA or in clinical development. In addition, Private equity firms are taking a stake in ownership while also funding biotech and emerging pharmaceutical companies.
While the FTC’s proposed rulemaking would affect every industry, the impact it could have on biopharma and biotech companies is unique due to the technologically advanced and secretive nature of the research and information gathered and its value to other companies.
The buyout will grant Leap Therapeutics access to Flame Bioscience’s portfolio, which includes a clinical-stage monoclonal antibody that is under investigation as a potential treatment for gastric, gastroesophageal junction, and pancreatic cancers.
Drugmakers are prioritizing complex biotech medicines over treatments that can be given as pills because recent U.S. legislation gives biologics a longer runway before becoming subject to government price limits, top industry executives said this week.
The two companies first collaborated on gene-editing medicines in 2018, when Vertex made a $30 million upfront payment in a cystic fibrosis deal. In 2021, Vertex pledged up to $1.2 billion in milestone payments to expand this partnership to include ex vivo next-generation cell therapies for diabetes and blood diseases.